KR20160133563A - 다이하이드로피리미딘 화합물 및 이의 약제학적 용도 - Google Patents
다이하이드로피리미딘 화합물 및 이의 약제학적 용도 Download PDFInfo
- Publication number
- KR20160133563A KR20160133563A KR1020167029448A KR20167029448A KR20160133563A KR 20160133563 A KR20160133563 A KR 20160133563A KR 1020167029448 A KR1020167029448 A KR 1020167029448A KR 20167029448 A KR20167029448 A KR 20167029448A KR 20160133563 A KR20160133563 A KR 20160133563A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- mmol
- methyl
- title compound
- morpholin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CNN1CC*CC1 Chemical compound CNN1CC*CC1 0.000 description 8
- RIXUJNFXNKAYRA-MBABXSBOSA-N CC(C)(CC1N(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Br)c3)ccc3F)=C2C(OC)=O)CCOC1)C(O)=O Chemical compound CC(C)(CC1N(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Br)c3)ccc3F)=C2C(OC)=O)CCOC1)C(O)=O RIXUJNFXNKAYRA-MBABXSBOSA-N 0.000 description 1
- LLHWYRNQKYMHPZ-MBABXSBOSA-N CC(C)(CC1N(CC(NC(c2ncc[s]2)=N[C@H]2c(ccc(F)c3)c3Cl)=C2C(OC)=O)CCOC1)C(O)=O Chemical compound CC(C)(CC1N(CC(NC(c2ncc[s]2)=N[C@H]2c(ccc(F)c3)c3Cl)=C2C(OC)=O)CCOC1)C(O)=O LLHWYRNQKYMHPZ-MBABXSBOSA-N 0.000 description 1
- WOAXPNLTYXUPCU-WTIAFYNJSA-N CC(C)[C@H]1OCCN(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Cl)c3)ccc3F)=C2C(OC)=O)[C@@H]1CCC(O)=O Chemical compound CC(C)[C@H]1OCCN(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Cl)c3)ccc3F)=C2C(OC)=O)[C@@H]1CCC(O)=O WOAXPNLTYXUPCU-WTIAFYNJSA-N 0.000 description 1
- JADFSSHZASIPJJ-UHFFFAOYSA-N CC(C)c1c(C)[o]cn1 Chemical compound CC(C)c1c(C)[o]cn1 JADFSSHZASIPJJ-UHFFFAOYSA-N 0.000 description 1
- LLYBOQJNOCWNPF-ZDUSSCGKSA-N CC(NC(c1ncc[s]1)=N[C@H]1c(c(Br)c2)ccc2F)=C1C(OC)=O Chemical compound CC(NC(c1ncc[s]1)=N[C@H]1c(c(Br)c2)ccc2F)=C1C(OC)=O LLYBOQJNOCWNPF-ZDUSSCGKSA-N 0.000 description 1
- OLFVEGGCEAETFY-AWEZNQCLSA-N CCOC(C1=C(C)NC(c2ncc[s]2)=N[C@H]1c(ccc(Cl)c1)c1Cl)=O Chemical compound CCOC(C1=C(C)NC(c2ncc[s]2)=N[C@H]1c(ccc(Cl)c1)c1Cl)=O OLFVEGGCEAETFY-AWEZNQCLSA-N 0.000 description 1
- CZVDQFYWJLGGKP-LGHNAOJLSA-N CCOC(C1=C(CN2C(CC(C)C(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O Chemical compound CCOC(C1=C(CN2C(CC(C)C(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O CZVDQFYWJLGGKP-LGHNAOJLSA-N 0.000 description 1
- KOBKCMGIKTWYND-MRNPHLECSA-N CCOC(C1=C(CN2CC(CC(C)(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2CC(CC(C)(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O KOBKCMGIKTWYND-MRNPHLECSA-N 0.000 description 1
- SVJPTUZYYNYIQZ-MRNPHLECSA-N CCOC(C1=C(CN2CC(CC(C)(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2CC(CC(C)(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O SVJPTUZYYNYIQZ-MRNPHLECSA-N 0.000 description 1
- JILWUJXLKILCMN-NHLOTGQUSA-N CCOC(C1=C(CN2C[C@@H](CC(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1F)ccc1F)=O Chemical compound CCOC(C1=C(CN2C[C@@H](CC(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1F)ccc1F)=O JILWUJXLKILCMN-NHLOTGQUSA-N 0.000 description 1
- TYFUQWNKMCKAGV-VFNWGFHPSA-N CCOC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O Chemical compound CCOC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O TYFUQWNKMCKAGV-VFNWGFHPSA-N 0.000 description 1
- AWQQRHKGJGKHPZ-TUUUUVLKSA-N CCOC(C1=C(CN2C[C@@H](CCCC(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2C[C@@H](CCCC(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O AWQQRHKGJGKHPZ-TUUUUVLKSA-N 0.000 description 1
- PWWYTMOJALFYBZ-JPYJTQIMSA-N CCOC(C1=C(CN2C[C@@H](CCCC3(CC3)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2C[C@@H](CCCC3(CC3)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O PWWYTMOJALFYBZ-JPYJTQIMSA-N 0.000 description 1
- GMHYVDZYSVBDCY-ZIGQVCHUSA-N CCOC(C1=C(CN2[C@H](C(C)CC(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2[C@H](C(C)CC(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O GMHYVDZYSVBDCY-ZIGQVCHUSA-N 0.000 description 1
- RXZVIECXRPSAIF-FEIWCMAGSA-N CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O RXZVIECXRPSAIF-FEIWCMAGSA-N 0.000 description 1
- PDDRTIUHRLVHRH-FEIWCMAGSA-N CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Cl)=O Chemical compound CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Cl)=O PDDRTIUHRLVHRH-FEIWCMAGSA-N 0.000 description 1
- RNJUXUXNQNQCOM-VFNWGFHPSA-N CCOC(C1=C(CN2[C@H](CCC(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O Chemical compound CCOC(C1=C(CN2[C@H](CCC(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O RNJUXUXNQNQCOM-VFNWGFHPSA-N 0.000 description 1
- FVBZRQASAZMRGV-FGCOXFRFSA-N CCOC(C1=C(CN2[C@H](CCC(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2[C@H](CCC(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O FVBZRQASAZMRGV-FGCOXFRFSA-N 0.000 description 1
- UUFLZTOLFVMDMA-WTGRHJARSA-N CCOC(C1=C(CN2[C@H](CCC(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2[C@H](CCC(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O UUFLZTOLFVMDMA-WTGRHJARSA-N 0.000 description 1
- HSONDHMYNAZDQC-WTGRHJARSA-N CCOC(C1=C(CN2[C@H](CCC(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Cl)=O Chemical compound CCOC(C1=C(CN2[C@H](CCC(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Cl)=O HSONDHMYNAZDQC-WTGRHJARSA-N 0.000 description 1
- WBEPIQBAZVECDL-ZHRRBRCNSA-N COC(C1=C(CN2C[C@@H](CCC(CC(O)=O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound COC(C1=C(CN2C[C@@H](CCC(CC(O)=O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O WBEPIQBAZVECDL-ZHRRBRCNSA-N 0.000 description 1
- CCVSZMHYKHZCJN-VLIAUNLRSA-N COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O CCVSZMHYKHZCJN-VLIAUNLRSA-N 0.000 description 1
- CCVSZMHYKHZCJN-XOBRGWDASA-N COC(C1=C(CN2C[C@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound COC(C1=C(CN2C[C@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O CCVSZMHYKHZCJN-XOBRGWDASA-N 0.000 description 1
- FDEANYCYFPZZRS-VLIAUNLRSA-N COC(C1=C(CN2[C@H](CCC(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound COC(C1=C(CN2[C@H](CCC(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O FDEANYCYFPZZRS-VLIAUNLRSA-N 0.000 description 1
- UOCFNLNJEUFKLO-UHFFFAOYSA-N Cc1nc(C2CC2)c[s]1 Chemical compound Cc1nc(C2CC2)c[s]1 UOCFNLNJEUFKLO-UHFFFAOYSA-N 0.000 description 1
- GIWQSPITLQVMSG-UHFFFAOYSA-N Cc1ncc[n]1C Chemical compound Cc1ncc[n]1C GIWQSPITLQVMSG-UHFFFAOYSA-N 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N Cc1ncc[s]1 Chemical compound Cc1ncc[s]1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410126202 | 2014-03-28 | ||
| CN201410126202.0 | 2014-03-28 | ||
| CN201410596489.3 | 2014-10-29 | ||
| CN201410596489 | 2014-10-29 | ||
| PCT/CN2015/075299 WO2015144093A1 (en) | 2014-03-28 | 2015-03-27 | Dihydropyrimidine compounds and their application in pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160133563A true KR20160133563A (ko) | 2016-11-22 |
Family
ID=54160517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167029448A Withdrawn KR20160133563A (ko) | 2014-03-28 | 2015-03-27 | 다이하이드로피리미딘 화합물 및 이의 약제학적 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9771358B2 (enExample) |
| EP (1) | EP3122747B1 (enExample) |
| JP (1) | JP2017512789A (enExample) |
| KR (1) | KR20160133563A (enExample) |
| CN (1) | CN104945395B (enExample) |
| AU (1) | AU2015236982B2 (enExample) |
| CA (1) | CA2938050A1 (enExample) |
| MX (1) | MX2016012573A (enExample) |
| MY (1) | MY196243A (enExample) |
| RU (1) | RU2682672C2 (enExample) |
| SG (1) | SG11201605896WA (enExample) |
| WO (1) | WO2015144093A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2794565B1 (en) | 2011-12-21 | 2017-07-26 | Novira Therapeutics Inc. | Hepatitis b antiviral agents |
| CA2881057C (en) | 2012-08-28 | 2020-10-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| JP6466348B2 (ja) | 2013-02-28 | 2019-02-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 |
| HUE033542T2 (en) | 2013-04-03 | 2017-12-28 | Janssen Sciences Ireland Uc | Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B |
| HUE040446T2 (hu) | 2013-05-17 | 2019-03-28 | Janssen Sciences Ireland Uc | Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére |
| TW202126620A (zh) | 2013-05-17 | 2021-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| WO2015011281A1 (en) | 2013-07-25 | 2015-01-29 | Janssen R&D Ireland | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| KR102284944B1 (ko) | 2013-11-27 | 2021-08-03 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 다이하이드로피리미딘 유도체 및 이의 중간산물의 제조 방법 |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| JP6553059B2 (ja) | 2014-02-05 | 2019-07-31 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｈｂｖ感染の治療のための併用療法 |
| PL3102572T3 (pl) | 2014-02-06 | 2019-04-30 | Janssen Sciences Ireland Uc | Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B |
| EP3271019A1 (en) | 2015-03-19 | 2018-01-24 | Novira Therapeutics Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| WO2017011552A1 (en) * | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| AR106192A1 (es) | 2015-09-29 | 2017-12-20 | Novira Therapeutics Inc | Formas cristalinas de un agente antiviral contra la hepatitis b |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| WO2017181141A2 (en) | 2016-04-15 | 2017-10-19 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
| WO2017198201A1 (en) * | 2016-05-19 | 2017-11-23 | Sunshine Lake Pharma Co., Ltd. | Crystalline form, salt and complex of dihydropyrimidine derivative, and uses thereof in medicine |
| EP3468561A4 (en) | 2016-06-10 | 2019-12-04 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN107674072B (zh) * | 2016-08-01 | 2020-11-24 | 广东东阳光药业有限公司 | 二氢嘧啶衍生物及其酸加成物的制备方法 |
| JP7139568B2 (ja) | 2016-11-18 | 2022-09-21 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | ジヒドロピリミジン化合物並びにその調製方法及び使用 |
| US11166954B2 (en) | 2016-11-18 | 2021-11-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| KR102665544B1 (ko) * | 2017-06-26 | 2024-05-14 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 디하이드로피리미딘 화합물 및 약제에서의 이의 용도 |
| EP3645516A4 (en) | 2017-06-27 | 2021-07-07 | Janssen Pharmaceutica NV | HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS |
| SG11202001685TA (en) | 2017-08-28 | 2020-03-30 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| MX2020004838A (es) | 2017-11-02 | 2020-10-16 | Aicuris Gmbh & Co Kg | Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb). |
| EA202091113A1 (ru) | 2017-11-02 | 2020-08-28 | Айкурис Гмбх Унд Ко. Кг | Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv) |
| US10723733B2 (en) | 2017-12-06 | 2020-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2019113173A1 (en) | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| SG11202007097QA (en) | 2018-03-14 | 2020-08-28 | Janssen Sciences Ireland Unlimited Co | Capsid assembly modulator dosing regimen |
| US10729688B2 (en) | 2018-03-29 | 2020-08-04 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| CN108329308B (zh) | 2018-05-16 | 2022-11-01 | 四川科伦博泰生物医药股份有限公司 | 一种二氢嘧啶类化合物的固体形式及其制备方法 |
| CN109021015B (zh) * | 2018-07-12 | 2019-12-03 | 山东大学 | 二氢嘧啶-磷酰胺类衍生物及其制备方法与应用 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| TW202024093A (zh) | 2018-09-21 | 2020-07-01 | 美商安塔製藥公司 | 作為抗病毒劑之官能化雜環 |
| AR116947A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
| US20220009945A1 (en) | 2018-11-02 | 2022-01-13 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-thiazole[5,4-c]pyridines active against the hepatitis b virus (hbv) |
| PY1991611A (es) | 2018-11-02 | 2022-03-14 | Aicuris Gmbh & Co Kg | Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) |
| AR117188A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
| PY1991606A (es) | 2018-11-02 | 2022-02-10 | Aicuris Gmbh & Co Kg | Nueva urea 6,7-dihidro-4h-pirazolo [4,3-c] piridinas activas contra el virus de la hepatitis b (vhb) |
| EP3883570A4 (en) | 2018-11-21 | 2022-07-13 | Enanta Pharmaceuticals, Inc. | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS |
| TW202035412A (zh) * | 2018-12-20 | 2020-10-01 | 比利時商健生藥品公司 | 雜芳基二氫嘧啶衍生物和治療ｂ型肝炎感染之方法 |
| AU2020223865A1 (en) | 2019-02-22 | 2021-07-15 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| KR20220002498A (ko) | 2019-04-30 | 2022-01-06 | 아이쿠리스 게엠베하 운트 코. 카게 | B형 간염 바이러스 (hbv)에 대해 활성인 신규 인돌리진-2-카르복스아미드 |
| MX2021013086A (es) | 2019-04-30 | 2021-11-17 | Aicuris Gmbh & Co Kg | Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb). |
| US20220306647A1 (en) | 2019-04-30 | 2022-09-29 | Aicuris Gmbh & Co. Kg | Novel indole-2-carboxamides active against the hepatitus b virus (hbv) |
| EP3962909B1 (en) | 2019-04-30 | 2023-10-04 | AiCuris GmbH & Co. KG | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
| BR112021021454A2 (pt) | 2019-05-06 | 2021-12-21 | Janssen Sciences Ireland Unlimited Co | Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| CA3140690A1 (en) * | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CN110615797A (zh) * | 2019-10-11 | 2019-12-27 | 李丽丽 | 用于治疗乙型肝炎的化合物及其用途 |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| UY39569A (es) | 2020-12-17 | 2022-07-29 | Astrazeneca Ab | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas |
| WO2022166923A1 (zh) | 2021-02-05 | 2022-08-11 | 和博医药有限公司 | 苯基二氢嘧啶类化合物及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0202654A3 (en) | 1985-05-20 | 1987-12-16 | E.R. Squibb & Sons, Inc. | 5-carboxy-1,4-dihydropyrimidine derivatives |
| GB8906168D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| SE9702564D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | New compounds |
| SE9702563D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | Compounds |
| DE19817265A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| DE19817262A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue 2-heterocyclisch substituierte Dihydropyrimidine |
| WO2000058302A1 (de) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b |
| DE10012549A1 (de) | 2000-03-15 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012823A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013126A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013125A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| CN101104604B (zh) | 2006-07-10 | 2011-03-02 | 北京摩力克科技有限公司 | 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101104617B (zh) | 2006-07-10 | 2010-06-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101225084A (zh) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101328170B (zh) | 2007-06-18 | 2011-09-14 | 张中能 | 一种氟苯基-取代噻唑二氢嘧啶 |
| WO2008154819A1 (fr) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Thiazolyl-dihydropyrimidines à substitution carbéthoxy |
| PT2514750E (pt) * | 2007-06-18 | 2014-01-23 | Sunshine Lake Pharma Co Ltd | Tiazolil dihidropirimidinas substituídas com bromo-fenilo |
| WO2008154820A1 (fr) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Thiazolyl-dihydropyrimidines à substitution carbéthoxy |
| CN101744823B (zh) | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | 一种二氢嘧啶类化合物的固体分散体及其药用制剂 |
| WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
| CN101575318B (zh) | 2009-06-25 | 2012-02-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途 |
| US9487534B2 (en) | 2011-08-02 | 2016-11-08 | Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California | Modulators of virus assembly as antiviral agents |
| AR089671A1 (es) | 2012-01-06 | 2014-09-10 | Janssen R & D Ireland | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| MY182403A (en) * | 2012-08-24 | 2021-01-25 | Sunshine Lake Pharma Co Ltd | Dihydropyrimidine compounds and their application in pharmaceuticals |
| CN103664897B (zh) | 2012-09-01 | 2018-04-03 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN103664925B (zh) | 2012-09-07 | 2018-01-23 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| CA2881322A1 (en) * | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CN103664899B (zh) | 2012-09-11 | 2017-06-16 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| HK1215030A1 (zh) | 2012-11-09 | 2016-08-12 | Indiana University Research And Technology Corporation | 用於hbv組裝效應劑的替代用途 |
| MX2015013363A (es) | 2013-03-20 | 2016-01-08 | Univ Indiana Res & Tech Corp | Heteroarildihidropirimidina (hap) fluorescente: tinte de diagnostico para nucleos de virus de la hep b (hbv) en celulas. |
| PE20151951A1 (es) | 2013-05-17 | 2015-12-26 | Hoffmann La Roche | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b |
| CA2920415A1 (en) | 2013-11-19 | 2015-05-28 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
| CN104650069B (zh) | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4-甲基二氢嘧啶类化合物及其在药物中的应用 |
| CN104650070B (zh) | 2013-11-25 | 2018-09-14 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| KR102284944B1 (ko) * | 2013-11-27 | 2021-08-03 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 다이하이드로피리미딘 유도체 및 이의 중간산물의 제조 방법 |
| PL3114128T3 (pl) | 2014-03-07 | 2019-06-28 | F. Hoffmann-La Roche Ag | Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B |
| EP3150600B1 (en) | 2014-05-30 | 2018-06-27 | Qilu Pharmaceutical Co., Ltd. | Dihydropyrimido loop derivative as hbv inhibitor |
-
2015
- 2015-03-27 MX MX2016012573A patent/MX2016012573A/es unknown
- 2015-03-27 EP EP15769748.3A patent/EP3122747B1/en active Active
- 2015-03-27 US US15/116,226 patent/US9771358B2/en active Active
- 2015-03-27 SG SG11201605896WA patent/SG11201605896WA/en unknown
- 2015-03-27 CN CN201510141969.5A patent/CN104945395B/zh active Active
- 2015-03-27 JP JP2016558407A patent/JP2017512789A/ja active Pending
- 2015-03-27 MY MYPI2016702906A patent/MY196243A/en unknown
- 2015-03-27 RU RU2016138735A patent/RU2682672C2/ru active
- 2015-03-27 KR KR1020167029448A patent/KR20160133563A/ko not_active Withdrawn
- 2015-03-27 WO PCT/CN2015/075299 patent/WO2015144093A1/en not_active Ceased
- 2015-03-27 AU AU2015236982A patent/AU2015236982B2/en active Active
- 2015-03-27 CA CA2938050A patent/CA2938050A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN104945395A (zh) | 2015-09-30 |
| AU2015236982B2 (en) | 2017-12-14 |
| CN104945395B (zh) | 2018-01-23 |
| EP3122747B1 (en) | 2020-05-20 |
| CA2938050A1 (en) | 2015-10-01 |
| JP2017512789A (ja) | 2017-05-25 |
| SG11201605896WA (en) | 2016-08-30 |
| WO2015144093A1 (en) | 2015-10-01 |
| EP3122747A1 (en) | 2017-02-01 |
| RU2016138735A3 (enExample) | 2018-05-03 |
| US20160347746A1 (en) | 2016-12-01 |
| MX2016012573A (es) | 2018-02-19 |
| RU2682672C2 (ru) | 2019-03-20 |
| RU2016138735A (ru) | 2018-05-03 |
| AU2015236982A1 (en) | 2016-08-11 |
| MY196243A (en) | 2023-03-24 |
| EP3122747A4 (en) | 2017-11-15 |
| US9771358B2 (en) | 2017-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9771358B2 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| KR102667040B1 (ko) | 디하이드로피리미딘 화합물 및 약제에서의 이의 용도 | |
| RU2678990C1 (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| KR102148678B1 (ko) | 다이하이드로피리미딘 화합물 및 이의 약제학적 용도 | |
| KR102665544B1 (ko) | 디하이드로피리미딘 화합물 및 약제에서의 이의 용도 | |
| CN104650070A (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CA3079557C (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| HK1228400B (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1228400A1 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1224286B (en) | Dihydropyrimidine compounds and their application in pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20161021 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20191126 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |